Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 69

1.

[Standard uptake value of 18F-fluorine-2-deoxyglucose is correlated with the expression of estrogen receptor in duct carcinoma of breast].

Wen GH, Feng YL, Deng HF, Yu FZ, Liu DJ, Yuan JW, He XH, Huang KM, Liu SS, Yang M.

Sichuan Da Xue Xue Bao Yi Xue Ban. 2008 May;39(3):448-50. Chinese.

PMID:
18575338
2.

Clinicopathological and prognostic relevance of uptake level using 18F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in primary breast cancer.

Ueda S, Tsuda H, Asakawa H, Shigekawa T, Fukatsu K, Kondo N, Yamamoto M, Hama Y, Tamura K, Ishida J, Abe Y, Mochizuki H.

Jpn J Clin Oncol. 2008 Apr;38(4):250-8. doi: 10.1093/jjco/hyn019.

PMID:
18407934
4.

The effects of estrogen, progesterone, and C-erbB-2 receptor states on 18F-FDG uptake of primary breast cancer lesions.

Mavi A, Cermik TF, Urhan M, Puskulcu H, Basu S, Yu JQ, Zhuang H, Czerniecki B, Alavi A.

J Nucl Med. 2007 Aug;48(8):1266-72. Epub 2007 Jul 13.

5.

Dynamic and static approaches to quantifying 18F-FDG uptake for measuring cancer response to therapy, including the effect of granulocyte CSF.

Doot RK, Dunnwald LK, Schubert EK, Muzi M, Peterson LM, Kinahan PE, Kurland BF, Mankoff DA.

J Nucl Med. 2007 Jun;48(6):920-5. Epub 2007 May 15.

6.

Positron emission mammography: correlation of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 status and 18F-FDG.

Wang CL, MacDonald LR, Rogers JV, Aravkin A, Haseley DR, Beatty JD.

AJR Am J Roentgenol. 2011 Aug;197(2):W247-55. doi: 10.2214/AJR.11.6478.

PMID:
21785049
7.

Comparison of standardized uptake value of 18F-FDG-PET-CT with 21-gene recurrence score in estrogen receptor-positive, HER2-negative breast cancer.

Ahn SG, Lee JH, Lee HW, Jeon TJ, Ryu YH, Kim KM, Sohn J, Yun M, Lee SA, Jeong J, Kim SI.

PLoS One. 2017 Apr 18;12(4):e0175048. doi: 10.1371/journal.pone.0175048. eCollection 2017.

8.

The relationship between FDG uptake in PET scans and biological behavior in breast cancer.

Shimoda W, Hayashi M, Murakami K, Oyama T, Sunagawa M.

Breast Cancer. 2007;14(3):260-8.

9.

18F-FDG PET of locally invasive breast cancer and association of estrogen receptor status with standardized uptake value: microarray and immunohistochemical analysis.

Osborne JR, Port E, Gonen M, Doane A, Yeung H, Gerald W, Cook JB, Larson S.

J Nucl Med. 2010 Apr;51(4):543-50. doi: 10.2967/jnumed.108.060459. Epub 2010 Mar 17.

10.

Role of FDG-PET/CT in evaluating surgical outcomes of operable breast cancer--usefulness for malignant grade of triple-negative breast cancer.

Ohara M, Shigematsu H, Tsutani Y, Emi A, Masumoto N, Ozaki S, Kadoya T, Okada M.

Breast. 2013 Oct;22(5):958-63. doi: 10.1016/j.breast.2013.05.003. Epub 2013 Jun 10.

PMID:
23756383
11.

Between-patient and within-patient (site-to-site) variability in estrogen receptor binding, measured in vivo by 18F-fluoroestradiol PET.

Kurland BF, Peterson LM, Lee JH, Linden HM, Schubert EK, Dunnwald LK, Link JM, Krohn KA, Mankoff DA.

J Nucl Med. 2011 Oct;52(10):1541-9. doi: 10.2967/jnumed.111.091439. Epub 2011 Sep 8.

12.

Preoperative FDG-PET for axillary metastases in patients with breast cancer.

Chung A, Liou D, Karlan S, Waxman A, Fujimoto K, Hagiike M, Phillips EH.

Arch Surg. 2006 Aug;141(8):783-8; discussion 788-9.

PMID:
16924086
13.

Standardized uptake values for breast carcinomas assessed by fluorodeoxyglucose-positron emission tomography correlate with prognostic factors.

Ikenaga N, Otomo N, Toyofuku A, Ueda Y, Toyoda K, Hayashi T, Nishikawa K, Tanaka M.

Am Surg. 2007 Nov;73(11):1151-7.

PMID:
18092653
14.

Breast cancer with low FDG uptake: characterization by means of dual-time point FDG-PET/CT.

Zytoon AA, Murakami K, El-Kholy MR, El-Shorbagy E, Ebied O.

Eur J Radiol. 2009 Jun;70(3):530-8. doi: 10.1016/j.ejrad.2008.01.045. Epub 2008 Apr 18.

PMID:
18395387
15.

Positron tomographic assessment of estrogen receptors in breast cancer: comparison with FDG-PET and in vitro receptor assays.

Dehdashti F, Mortimer JE, Siegel BA, Griffeth LK, Bonasera TJ, Fusselman MJ, Detert DD, Cutler PD, Katzenellenbogen JA, Welch MJ.

J Nucl Med. 1995 Oct;36(10):1766-74.

16.

Correlation between 18F-fluorodeoxyglucose Positron Emission Tomography/computed Tomography and Clinicopathological Features in Invasive Ductal Carcinoma of the Breast.

Ito M, Shien T, Kaji M, Mizoo T, Iwamoto T, Nogami T, Motoki T, Taira N, Doihara H, Miyoshi S.

Acta Med Okayama. 2015;69(6):333-8.

17.

Accuracy of PET for diagnosis of solid pulmonary lesions with 18F-FDG uptake below the standardized uptake value of 2.5.

Hashimoto Y, Tsujikawa T, Kondo C, Maki M, Momose M, Nagai A, Ohnuki T, Nishikawa T, Kusakabe K.

J Nucl Med. 2006 Mar;47(3):426-31.

18.
19.

Glucose metabolism of breast cancer assessed by 18F-FDG PET: histologic and immunohistochemical tissue analysis.

Avril N, Menzel M, Dose J, Schelling M, Weber W, Jänicke F, Nathrath W, Schwaiger M.

J Nucl Med. 2001 Jan;42(1):9-16.

20.

PET-based estradiol challenge as a predictive biomarker of response to endocrine therapy in women with estrogen-receptor-positive breast cancer.

Dehdashti F, Mortimer JE, Trinkaus K, Naughton MJ, Ellis M, Katzenellenbogen JA, Welch MJ, Siegel BA.

Breast Cancer Res Treat. 2009 Feb;113(3):509-17. doi: 10.1007/s10549-008-9953-0. Epub 2008 Mar 9.

Supplemental Content

Support Center